Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
21Shares launches Jito Staked SOL ETP (JSOL), offering higher Solana yield exposure

21Shares launches Jito Staked SOL ETP (JSOL), offering higher Solana yield exposure

币界网币界网2026/01/29 08:13
Show original
According to CoinWorld, 21Shares has launched the world's first JitoSOL Exchange Traded Product (ETP). JitoSOL is the leading liquid staking token on the Solana platform. The 21Shares Jito Staked SOL ETP (JSOL) provides investors with a liquid, exchange-traded channel for JitoSOL, enabling them to fully benefit from Solana's price fluctuations and receive dual returns from both standard staking rewards and network transaction fees. This ETP has been listed on Euronext Amsterdam and Euronext Paris, with a total expense ratio of 0.99%.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53